Stocks · News reference
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.
Why Is Contineum Therapeutics Stock Falling Monday?
BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $275 to $287.